Arrow inks $227M licensing pact for RSV therapy

Arrow Therapeutics has nailed down a big licensing deal with Novartis on A604444, an experimental treatment for Respiratory Syncytial Virus. Novartis will pay $10 million up front and up to $217 million more in milestones for a successful development program. Novartis also gains first-rights to the bargaining table for additional molecules in follow-up development at Arrow.

"A-60444 is a first-in-class product for the treatment of RSV," says Arrow CEO Ken Powell. "This is an area of high unmet medical need, and one which is gaining increasing recognition of its importance by the medical community. For Arrow in particular, the deal with Novartis is a validation of both our model and our R&D capability and I am very satisfied with the outcome."

- read this release for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.